Library

By pinki shah / May 14, 2022

Displaying 1,651 - 1,675 of 2,995

EGFR, K-RAS and ERBB2 Mutations in NSCLC

EGFR, K-RAS and ERBB2 Mutations in NSCLC

By: Edgardo S. Santos Castillero, MD, FACP

EGFR, K-RAS and ERBB2 Mutations in NSCLC

EGFR, K-RAS and ERBB2 Mutations in NSCLC

By: Edgardo S. Santos Castillero, MD, FACP

Novel Treatment for Unresectable Stage III NSCLC

Novel Treatment for Unresectable Stage III NSCLC

By: Edgardo S. Santos Castillero, MD, FACP

Novel Treatment for Unresectable Stage III NSCLC

Novel Treatment for Unresectable Stage III NSCLC

By: Edgardo S. Santos Castillero, MD, FACP

Small Cell Lung Cancer

Small Cell Lung Cancer

By: Edgardo S. Santos Castillero, MD, FACP, FASCO

First-Line Targeted Therapies in NSCLC: What’s New?

First-Line Targeted Therapies in NSCLC: What’s New?

By: Edgardo S. Santos Castillero, MD, FACP, FASCO

HER-3 as a New Target in NSCLC

HER-3 as a New Target in NSCLC

By: Edgardo S. Santos, MD

HER-3 as a New Target in NSCLC

HER-3 as a New Target in NSCLC

By: Edgardo S. Santos, MD

Liquid Biopsy in the Management of Lung Cancer

Liquid Biopsy in the Management of Lung Cancer

By: Edgardo S. Santos, MD, FACP

EGFR Common and Uncommon Mutations & What Is Next For This Patient Population

EGFR Common and Uncommon Mutations & What Is Next For This Patient Population

By: Edgardo S. Santos, MD, FACP

EGFR & ALK: Where are We Now

EGFR & ALK: Where are We Now

By: Edgardo S. Santos, MD, FACP

New Landscape of Mutant EGFR & ALK Lung Cancer Patients

New Landscape of Mutant EGFR & ALK Lung Cancer Patients

By: Edgardo S. Santos, MD, FACP

RET, MET, & NTRK in Non-Small Cell Lung Cancer

RET, MET, & NTRK in Non-Small Cell Lung Cancer

By: Edgardo S. Santos, MD, FACP

RET, MET, and BRAF Mutant Lung Cancer Tumors

RET, MET, and BRAF Mutant Lung Cancer Tumors

By: Edgardo S. Santos, MD, FACP

Other Driver Mutations: ROS-1, RET, HER-2, MET & Exon 20 Insertions

Other Driver Mutations: ROS-1, RET, HER-2, MET & Exon 20 Insertions

By: Edgardo S. Santos, MD, FACP

Targeted Therapy in Non-Squamous NSCLC: Where Are We and What Is Coming Up?

Targeted Therapy in Non-Squamous NSCLC: Where Are We and What Is Coming Up?

By: Edgardo S. Santos, MD, FACP

EGFR/ALK and ROS-1 Lung Cancer Management

EGFR/ALK and ROS-1 Lung Cancer Management

By: Edgardo S. Santos, MD, FACP

Lung Targeted Therapies IN NSCLC: EGFR, ALK, and ROS1

Lung Targeted Therapies IN NSCLC: EGFR, ALK, and ROS1

By: Edgardo S. Santos, MD, FACP

Advances in Targeted Therapy in Lung Cancer

Advances in Targeted Therapy in Lung Cancer

By: Edgardo S. Santos, MD, FACP

Lung Targeted Therapies IN NSCLC: EGFR, ALK, and ROS1

Lung Targeted Therapies IN NSCLC: EGFR, ALK, and ROS1

By: Edgardo S. Santos, MD, FACP

Advances in Targeted Therapy in Lung Cancer

Advances in Targeted Therapy in Lung Cancer

By: Edgardo S. Santos, MD, FACP

Dealing with EGFRex19del & L858R, ALK, and KRASg12c Genetic Aberrations

Dealing with EGFRex19del & L858R, ALK, and KRASg12c Genetic Aberrations

By: Edgardo S. Santos, MD, FACP

Dealing with EGFRex19del & L858R, ALK, and KRASg12c Genetic Aberrations

Dealing with EGFRex19del & L858R, ALK, and KRASg12c Genetic Aberrations

By: Edgardo S. Santos, MD, FACP

EGFR PKI Resistance and K-RAS Mutations

EGFR PKI Resistance and K-RAS Mutations

By: Edgardo S. Santos, MD, FACP

Targeted Therapy in Lung Cancer

Targeted Therapy in Lung Cancer

By: Edgardo S. Santos, MD, FACP